Fenoldopam and N-acetylcysteine for the prevention of radiographic contrast material-induced nephropathy:: A review

被引:15
|
作者
Walker, PD
Brokering, KL
Theobald, JC
机构
[1] St Louis Coll Pharm, Div Pharm Practice, St Louis, MO 63110 USA
[2] St Elizabeth Hosp, Dept Pharm, Belleville, IL USA
[3] Univ Alabama, Sch Med, Tuscaloosa, AL 35401 USA
[4] Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA
来源
PHARMACOTHERAPY | 2003年 / 23卷 / 12期
关键词
fenoldopam; N-acetylcysteine; nephropathy; radiographic contrast;
D O I
10.1592/phco.23.15.1617.31958
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Radiographic contrast material-induced nephropathy (RCIN) is the third most common cause of hospital-acquired renal insufficiency and has been associated with an increase in patient mortality Many strategies to prevent RCIN have been explored unsuccessfully. The standard of care remains hydration with 0.45% sodium chloride before and after administration of contrast material. Recently, N-acetylcysteine and fenoldopam have been studied to determine their efficacy in preventing RCIN. Of seven prospective studies using various dosing regimens of N-acetylcysteine, four revealed beneficial results. Although some discrepancies exist, the data strongly suggest that N-acetylcysteine has a role in patients at risk for the development of RCIN. The data for fenoldopam are more limited, with only one retrospective study showing benefit. Additional prospective data are required to determine if fenoldopam has a role in the prevention of RCIN.
引用
收藏
页码:1617 / 1626
页数:10
相关论文
共 50 条
  • [1] N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy:: Is the intravenous route best?
    Shalansky, SJ
    Vu, T
    Pate, GE
    Levin, A
    Humphries, KH
    Webb, JG
    PHARMACOTHERAPY, 2005, 25 (08): : 1095 - 1103
  • [2] Lessons in formulary management: The case of fenoldopam for radiographic contrast material-induced nephropathy
    De Shong, D
    Mathis, AS
    PHARMACOTHERAPY, 2004, 24 (06): : 819 - 820
  • [3] Randomized comparison of Fenoldopam and N-acetylcysteine to saline in the prevention of radio-contrast induced nephropathy
    Loutrianakis, E
    Stella, D
    Hussain, A
    Lewis, B
    Steen, L
    Sochanski, M
    Leya, F
    Grassman, E
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 327A - 327A
  • [4] Lessons in formulary management: The case of fenoldopam for radiographic contrast material-induced nephropathy - Reply
    Walker, PD
    Theobald, KL
    Theobald, JC
    PHARMACOTHERAPY, 2004, 24 (06): : 820 - 820
  • [5] N-acetylcysteine for Prevention of Contrast-Induced Nephropathy: A Narrative Review
    Jo, Sang-Ho
    KOREAN CIRCULATION JOURNAL, 2011, 41 (12) : 695 - 702
  • [6] The role of N-acetylcysteine in preventing radiographic contrast induced nephropathy
    Guru, V
    Fremes, SE
    CIRCULATION, 2003, 108 (17) : 460 - 460
  • [7] N-acetylcysteine in the prevention of contrast-induced nephropathy
    Fishbane, Steven
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (01): : 281 - 287
  • [8] Hypothermia, but not N-acetylcysteine or fenoldopam, prevents experimental contrast-induced nephropathy
    Dae, MW
    Gao, DW
    Stillson, CA
    Stone, GW
    Ursell, PC
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 48A - 48A
  • [9] Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN)
    Ng, Tien M. H.
    Shurmur, Scott W.
    Silver, Mary
    Nissen, Lindsay R.
    O'Leary, Edward L.
    Rigmaiden, Richard S.
    Cieciorka, Mike
    Porter, Laura L.
    Ineck, Beata A.
    Kline, Mary E.
    Puumala, Susan E.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 109 (03) : 322 - 328
  • [10] Evaluation of N-acetylcysteine for the prevention of contrast-induced nephropathy
    Richter, Sara K.
    Crannage, Andrew J.
    PHARMACOTHERAPY, 2013, 33 (10): : E182 - E183